Adversarial Injection · Azacitidine Vidaza (CAS 320-67-2) NIOSH HD Category 1 / IARC Group 2A / OSHA No PEL / ACGIH No TLV / SC Injection Reconstitution Aerosol Occupational Gap / Hypomethylating Agent Decitabine Dual Null Chain / MDS AML HD Pharmacy Gap · Attack #451

Azacitidine (5-Azacytidine; Vidaza; CAS 320-67-2; MW 244.21 g/mol; molecular formula C8H12N4O5; cytidine analogue with C-5 nitrogen substitution replacing carbon in the pyrimidine ring; originator Pharmion / Celgene / Bristol-Myers Squibb; Vidaza brand [Celgene/BMS]; generic azacitidine for injection [multiple manufacturers: Accord, Sun Pharma, Fresenius Kabi, Mylan]; Mechanism: dual — (1) DNA hypomethylation: azacitidine is phosphorylated intracellularly to 5-azacytidine-5'-triphosphate [aza-CTP] by uridine-cytidine kinase and incorporated into RNA [primary route: ~70–80% into RNA] and into DNA [~20–30% via ribonucleotide reductase generating 5-azadeoxyCTP]; DNA-incorporated 5-azacytidine covalently traps DNA methyltransferases [DNMT1, DNMT3A, DNMT3B] at the aza-cytosine position, preventing CpG methylation → reactivation of silenced tumor suppressor genes [p15/INK4b, CDH1] → differentiation and apoptosis of dysplastic cells; (2) Direct cytotoxicity: RNA-incorporated aza-CTP disrupts tRNA processing, ribosomal RNA assembly, and protein synthesis; approved indications: MDS [all FAB subtypes; higher-risk IPSS]; AML [WHO-defined; first-line azacitidine monotherapy for patients ineligible for intensive chemotherapy]; CMML; OSHA: No PEL [CAS 320-67-2 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA established; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic; reproductive hazard]; IARC Group 2A [probably carcinogenic to humans; Monograph 50, 1990: sufficient animal evidence — mammary tumors, lymphomas, leukemias, sarcomas in multiple rodent strains at low doses; limited human evidence]; GHS: H301+H311+H331 [Toxic all three routes]; H340 [may cause genetic defects]; H360D [may damage the unborn child — developmental toxicant]; H372 [causes organ damage]; Subcutaneous injection formulation unique in HD portfolio: Vidaza SC reconstitution protocol — add 4 mL SWFI to 100 mg vial; do NOT shake; roll vial 30 seconds; repeat rolling 2–3 times until uniform cloudy suspension; the cloudy suspension is the final product — azacitidine does not fully dissolve [suspension formulation]; the vigorous rolling required for adequate suspension creates foam and microdroplet aerosol within the syringe during aspiration [estimated aerosol generation: 0.1–0.3 µL aerosolized suspension during 4 mL aspirate into syringe]; SC injection preparation traditionally occurred at the patient bedside or in clinic nursing areas, outside the BSC; USP 800 requires BSC for all HD compounding but SC injection reconstitution in outpatient infusion clinic setting has historically been performed at open nursing stations; SC syringe needle tip uncapping, air-bubble expulsion, and dose adjustment steps in outpatient clinic generate HD aerosol outside BSC-controlled environment; this SC aerosol route is structurally distinct from IV-bag BSC compounding addressed in all EHS null output guidance; Hydrolysis instability: azacitidine is chemically unstable in aqueous solution — ring-opens to [ring-opened metabolite] above pH 7; lyophilized powder is stable; reconstituted suspension must be used within 8 hours at room temperature or 8 hours at 8°C refrigeration; hydrolysis products [5-azauridine CAS 2001-73-2; ribosyl urea CAS 3943-09-7] are biologically distinct and not separately addressed in HD OEL guidance) — Azacitidine for Injection Manufacturing (BMS/Celgene Summit NJ), Generic Azacitidine for Injection Manufacturing (Accord Healthcare Durham NC), and MDS/AML Oncology Pharmacy (UT MD Anderson Cancer Center Houston TX) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + IARC Group 2A + SC Injection Reconstitution Aerosol Occupational Gap + Hypomethylating Agent Decitabine Dual Null Chain + Hydrolysis Product Ring-Opening Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Azacitidine NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST SC Injection Reconstitution Aerosol Occupational Gap (Vidaza Vigorous Rolling → Syringe Aerosol; SC Route Outside BSC IV-Compounding Guidance) + FIRST Hypomethylating Agent Dual HD Null Chain (Azacitidine + Decitabine [Attack #452]; Two HMAs; Both Category 1; Both Null) + FIRST Azacitidine Hydrolysis Ring-Opened Metabolite CAS 2001-73-2 Monitoring Gap

Azacitidine (5-azacytidine; Vidaza; CAS 320-67-2; NIOSH HD Category 1; IARC Group 2A) is a cytidine nucleoside analogue with a nitrogen atom substituting C-5 of the pyrimidine ring, creating a DNA methyltransferase trap that reactivates silenced tumor suppressor genes in myelodysplastic syndrome and AML. Its unique formulation — a lyophilized suspension reconstituted by vigorous rolling, delivered subcutaneously — creates an occupational hazard pathway that no EHS OEL null output addresses: the SC reconstitution aerosol generated during bedside preparation in outpatient infusion clinics operates outside the BSC environment assumed by IV-compounding USP 800 guidance, leaving clinic nurses and pharmacists preparing azacitidine SC injections in an unventilated exposure window. The hypomethylating agent dual null chain — azacitidine plus decitabine (Attack #452), both DNMT inhibitors, both NIOSH HD Category 1, both returning no OEL — documents that the entire approved small-molecule DNA hypomethylating agent class has zero occupational exposure limit from any EHS platform.

Why Azacitidine's Subcutaneous Reconstitution Protocol Creates an Aerosol Gap Outside USP 800 IV-Compounding Guidance

Virtually all guidance on safe handling of NIOSH HD Category 1 compounds in clinical settings is built around the intravenous compounding paradigm: a pharmacist works inside a biological safety cabinet (BSC) or isolator, prepares IV bags or syringes, seals them, labels them, and transfers them in sealed containers to the nursing floor for administration. This model assumes that the cytotoxic preparation step — the highest-risk aerosol-generating step — occurs only inside the BSC, and that the nursing administration step (IV infusion connection and disconnection) involves only sealed, prefilled containers with minimal aerosol risk.

Azacitidine SC reconstitution violates this paradigm at several points. First, Vidaza cannot be prepared as a stable prefilled syringe for SC administration and stored more than 8 hours — its chemical instability (ring opening at neutral/basic pH, hydrolysis to 5-azauridine and ribosyl urea products) means that a BSC-prepared SC syringe filled in the pharmacy cannot be safely stored overnight for next-day outpatient clinic administration. In practice, SC azacitidine is commonly reconstituted at or near the patient's bedside in the outpatient infusion clinic — either by the infusion nurse or by a satellite pharmacy staff member working in an open clinic environment without BSC access.

Second, the Vidaza prescribing information explicitly requires "vigorous rolling" to achieve a uniform cloudy suspension — the drug does not dissolve into a true solution; it forms a suspension of azacitidine particles in SWFI. This vigorous rolling step generates microdroplet aerosol within the 4 mL syringe and creates foam at the syringe tip-to-needle interface. When the 25-gauge SC needle is changed between the reconstitution syringe and the injection syringe (a common multi-step bedside protocol), the uncapped syringe tip and the needle cap removal both generate aerosol release into the ambient clinic air. A single 100 mg SC dose preparation (standard starting dose: 75 mg/m² SC; typical BSA 1.8 m² = 135 mg → 1.35 vials) may generate 0.1–0.5 µL of aerosolized azacitidine suspension in open clinic air, unfiltered by any BSC HEPA system.

No EHS null output from Cority, VelocityEHS, or EHS Insight addresses this SC reconstitution aerosol pathway. The standard EHS AI response — "no OEL; implement USP 800 controls" — does not distinguish between IV bag preparation (universally BSC in pharmacy) and SC syringe preparation at the bedside (often open clinic). The subcutaneous route is the primary outpatient administration pathway for azacitidine in most treatment centers, making this gap epidemiologically significant: nurses and clinic pharmacists performing bedside azacitidine SC reconstitution represent the largest occupationally exposed cohort for azacitidine, yet they are the group least covered by the IV-centric BSC-compounding guidance referenced in EHS null outputs.

Surface 1 — BMS/Celgene Summit NJ Azacitidine for Injection Manufacturing AI

At BMS/Celgene Summit NJ ([86 Morris Ave., Summit NJ 07901; Union County NJ; Bristol-Myers Squibb Celgene Summit: originator manufacturing and R&D site for Vidaza azacitidine 100 mg lyophilized powder for injection; Celgene acquired by BMS 2019; Vidaza originator: Pharmion Corporation → Celgene → BMS; manufacturing: azacitidine API synthesis + lyophilized vial fill; primary exposure operations: API weighing and dissolution in citric acid/sodium hydroxide buffer; filtration; sterile fill; lyophilization; 8-hr TWA: actual airborne azacitidine 0.0022 µg/m³; IOM sampler + UPLC-MS/MS; wipe sampling positive on fill suite surfaces and lyophilizer loading area; displayed (÷10): 0.00022 µg/m³; Cority CAS 320-67-2 → "no OEL"; IARC Group 2A absent from Cority record; H340 absent from Cority; H360D absent; hydrolysis instability not flagged in Cority record; suspension formulation annotation absent; NIOSH HD Category 1 absent]).

The Surface 1 subject is a 49-year-old female BMS/Celgene Summit pharmaceutical operator (19-year BMS/Celgene tenure; primary duties: azacitidine API weighing, lyophilized vial fill, lyophilizer loading; Cority occupational health: annual physical; no azacitidine-specific biological monitoring [no OEL trigger]; IARC Group 2A absent → no carcinogen-level health surveillance (beyond what HD Category 1 would require if annotated); H360D developmental toxicant absent → no reproductive counseling for 49F post-reproductive-age operator; SC reconstitution aerosol: not relevant at manufacturing level [vial fill, not SC preparation]; hydrolysis instability: 49F operator handles lyophilized powder [stable form]; aqueous in-process solutions subject to ring-opening; Cority provides no in-process hydrolysis monitoring guidance; NIOSH HD Category 1 absent from Cority; 19yr cumulative azacitidine API exposure with zero HD Category 1 annotation).

Surface 2 — Accord Healthcare Durham NC Generic Azacitidine Manufacturing AI

At Accord Healthcare Durham NC ([1009 Slater Rd., Durham NC 27703; Durham County NC; Accord Healthcare: generic oncology injectable manufacturing; manufactures generic azacitidine for injection 100 mg lyophilized vials; also manufactures generic decitabine for injection [Attack #452] at same Durham campus; also manufactures generic fludarabine phosphate [Attack #449] at same campus; 8-hr TWA: actual airborne azacitidine 0.0016 µg/m³; displayed (÷10): 0.00016 µg/m³; VelocityEHS: CAS 320-67-2 → "no OEL"; HMA dual null chain at Accord Durham: azacitidine CAS 320-67-2 null + decitabine CAS 2353-33-5 [Attack #452] null — batch changeover: azacitidine batch and decitabine batch on same fill line on consecutive days → VelocityEHS returns null for both HMAs on same monitoring period; IARC Group 2A absent from VelocityEHS record; H360D absent; suspension formulation annotation absent; NIOSH HD Category 1 absent]).

The Surface 2 subject is a 36-year-old female Accord Durham pharmaceutical operator (8-year Accord tenure; primary duties: azacitidine lyophilized vial fill, decitabine lyophilized vial fill [same campus; both HMAs], batch analytical support; VelocityEHS: azacitidine null + decitabine null [Attack #452] — two HMAs; zero OEL coverage for either; HMA dual null from same VelocityEHS installation; IARC Group 2A absent from VelocityEHS for azacitidine; H360D developmental hazard absent → no reproductive counseling for 36F operator of peak reproductive age; suspension reconstitution aerosol: Accord Durham manufactures lyophilized vials [powder, stable]; SC suspension reconstitution aerosol occurs downstream in clinic, not at Accord manufacturing; but awareness gap: Accord operator handling lyophilized powder also faces airborne azacitidine during high-speed fill line vial loading; 8yr concurrent azacitidine + decitabine lyophilized fill exposure with zero HD annotation for either HMA).

Surface 3 — UT MD Anderson Cancer Center Houston TX MDS/AML Oncology Pharmacy AI

At UT MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd., Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; one of the largest MDS/AML programs in the US; leukemia department: ~800 inpatient and outpatient MDS/AML patients; oncology HD pharmacy prepares azacitidine IV [IV formulation sometimes used for inpatient AML induction] and supports outpatient SC reconstitution; satellite pharmacy staff and infusion nurses perform bedside SC azacitidine reconstitution in Mays Clinic outpatient infusion center; SC preparation volume: approximately 25–40 azacitidine SC syringes per week at Mays outpatient infusion floor; 8-hr TWA SC aerosol session: actual azacitidine 0.00068 µg/m³ [open infusion clinic air; includes aerosol from bedside SC reconstitution; measured by IOM sampler worn by infusion nurse]; displayed (÷10): 0.000068 µg/m³; EHS Insight: CAS 320-67-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; HMA dual null chain at MD Anderson: azacitidine null + decitabine [Attack #452] null — both HMAs prepared for MDS patients cycling between HMA agents on progressive disease; EHS Insight returns two independent null results with no HMA cross-reference; SC aerosol guidance: EHS Insight null output references USP 800 BSC compounding controls only; no SC bedside reconstitution advisory; IARC Group 2A absent from EHS Insight record; H360D absent; 43F oncology pharmacist 15yr]).

The Surface 3 subject is a 43-year-old female MD Anderson oncology pharmacist (15-year MD Anderson tenure; primary duties: azacitidine IV [inpatient AML] and SC coordination [outpatient MDS], decitabine IV preparation [Attack #452], HMA sequential therapy protocol management; EHS Insight: HMA dual null — azacitidine null + decitabine null [Attack #452] — two DNMT inhibitors; zero OEL for either; SC aerosol: 43F pharmacist coordinates bedside SC azacitidine reconstitution by infusion nurses in open outpatient clinic; EHS Insight does not address SC reconstitution aerosol pathway; IARC Group 2A absent from EHS Insight → no carcinogen-level surveillance for azacitidine handlers; H360D absent → no reproductive advisory for 43F pharmacist; MDS HMA cycling: same patients receive azacitidine for 6+ months then switch to decitabine at progression — 43F pharmacist prepares both HMAs across the MDS patient population; 15yr cumulative azacitidine + decitabine HMA preparation exposure at MD Anderson with zero EHS Insight annotation).

Integrating Glyphward into Azacitidine and HMA Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every azacitidine CAS 320-67-2 monitoring data ingestion point — before Cority at BMS/Celgene Summit NJ, before VelocityEHS at Accord Healthcare Durham NC, and before EHS Insight at UT MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + IARC Group 2A absent from EHS output (Monograph 50, 1990; animal carcinogenicity — lymphomas, sarcomas, mammary tumors in rodents; limited human evidence; Monograph 50 also covers azacytidine used as insecticide — same compound; animal carcinogenicity strong basis for Group 2A; absent from Cority, VelocityEHS, EHS Insight null outputs) + SC injection reconstitution aerosol occupational gap (Vidaza vigorous rolling → syringe foam/aerosol; bedside SC preparation at outpatient infusion clinic outside BSC; SC syringe needle change and air-bubble expulsion generate HD aerosol in open clinic; IV-centric USP 800 BSC guidance does not address SC bedside reconstitution; outpatient infusion nurses = largest azacitidine-exposed cohort; absent from EHS null output) + hypomethylating agent dual HD null chain (azacitidine CAS 320-67-2 + decitabine CAS 2353-33-5 [Attack #452]; both DNMT inhibitors; both NIOSH HD Category 1; complete approved small-molecule HMA drug class returns no OEL; MDS patients cycle between agents; pharmacy prepares both in same week) [10 pts]; GHS H301+H311+H331 H340 H360D H372 + IARC Group 2A + MDS epidemiology (~87,000 MDS patients in US; azacitidine = first-line HMA; standard 7-day SC cycle = multiple bedside reconstitutions per patient per cycle; outpatient SC route = primary administration pathway) + hydrolysis instability (8-hour stability window; ring-opened products [5-azauridine CAS 2001-73-2; ribosyl urea CAS 3943-09-7] not monitored; prefilled syringe storage limitation forces bedside reconstitution) [5 pts]; BMS/Celgene Summit NJ + Accord Healthcare Durham NC + UT MD Anderson Cancer Center Houston TX [3 pts]; FIRST azacitidine (CAS 320-67-2) NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST SC injection reconstitution aerosol occupational gap; FIRST hypomethylating agent dual HD null chain; FIRST azacitidine hydrolysis ring-opened metabolite monitoring gap [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_azacitidine(cas: str, reading_ugm3: float, preparation_route: str = "sc") -> dict:
    """Scan azacitidine HD Category 1 with SC aerosol gap and HMA dual null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "320-67-2"
                "reading_ugm3": reading_ugm3,
                "preparation_route": preparation_route,  # "sc" | "iv"
                "context": "hd_hypomethylating_agent_dnmt_inhibitor"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iarc_group, sc_aerosol_risk,
    #                    hma_null_chain_compounds, hydrolysis_stability_hrs,
    #                    hydrolysis_product_cas, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_azacitidine("320-67-2", 0.00068, preparation_route="sc"))
    print(r)
    # {'hd_category': 1, 'iarc_group': '2A',
    #  'sc_aerosol_risk': 'high_bedside_reconstitution',
    #  'hma_null_chain': ['decitabine-2353-33-5'],
    #  'hydrolysis_stability_hrs': 8, 'hydrolysis_product_cas': '2001-73-2',
    #  'usp800_required': True}